Bosso J A, Black P G, Matsen J M
Pediatr Infect Dis J. 1987 Apr;6(4):393-7. doi: 10.1097/00006454-198704000-00010.
A noncomparative pilot study was conducted to assess the potential usefulness of aztreonam in pulmonary exacerbations of cystic fibrosis. Of 27 patients initially enrolled 25 received sufficient courses of aztreonam therapy to be evaluable. All patients received 200 mg/kg/day of aztreonam in 4 equally divided doses administered intravenously. Of 57 isolates of Pseudomonas aeruginosa from pretherapy sputum cultures, 48 were susceptible to aztreonam in vitro as were 11 of 18 strains isolated at the conclusion of therapy. With treatment colony counts of P. aeruginosa in sputum were reduced by 3 log10 or more in 15 patients. It was totally (but temporarily) eradicated in 11 of these patients. Clinical scores and white blood cell counts improved significantly (P less than 0.05). Side effects of aztreonam were limited to transient elevations of liver enzymes occurring in 16 patients. Aztreonam merits further evaluation in a randomized, comparative trial with standard antibiotic therapy for cystic fibrosis.
进行了一项非对照性初步研究，以评估氨曲南在囊性纤维化肺部加重期的潜在效用。最初纳入的27例患者中，25例接受了足够疗程的氨曲南治疗，可进行评估。所有患者静脉注射氨曲南，剂量为200mg/kg/天，分4等份给药。治疗前痰培养分离出的57株铜绿假单胞菌中，48株在体外对氨曲南敏感，治疗结束时分离出的18株菌株中有11株敏感。治疗后，15例患者痰中铜绿假单胞菌的菌落计数降低了3个对数10或更多。其中11例患者的铜绿假单胞菌被完全（但只是暂时）清除。临床评分和白细胞计数显著改善（P<0.05）。氨曲南的副作用仅限于16例患者出现的肝酶短暂升高。氨曲南值得在一项针对囊性纤维化的随机对照试验中与标准抗生素疗法进行进一步评估。
